Key TakeawaysEli Lilly shares dropped more than 4% on Thursday as investors assessed the possible impact of a promising new weight-loss injection developed by Viking Therapeutics on the drugmaker’s own anti-obesity drug, Mounjaro.The stock's technicals, including bearish divergence and a decisive close beneath a multi-month uptrend line and the 50-day moving average, point to a potential reversal.Eli Lilly shares may encounter support on the chart from prior price action at $790, $725, and $625.A bars patte ...

Group 1: Company Performance - Eli Lilly's stock has increased by 136% since the beginning of 2023, significantly outperforming the S&P 500 and Nasdaq indices [1][2] - The company's revenue from its diabetes medication Mounjaro reached $5.2 billion in 2023, with a projected revenue run rate of $7.2 billion for 2024 [2] - Eli Lilly's stock has gained 51% in 2024 alone, reflecting strong market momentum [5] Group 2: Market Potential - The GLP-1 market, which includes Eli Lilly's treatments, is projected to be worth $100 billion by 2030, indicating substantial growth potential [3] - The FDA has approved expanded indications for some GLP-1 treatments, suggesting that the market size could exceed current forecasts [3] - Eli Lilly's recent FDA approval for its Alzheimer's medication, donanemab, opens up another multibillion-dollar market opportunity [4] Group 3: Stock Split Consideration - A stock split could be beneficial for Eli Lilly, as high share prices may deter some investors [5] - Historical trends show that companies with significant stock gains, like Nvidia and Tesla, have opted for stock splits [5] - While speculation exists regarding a potential stock split, there is no guarantee it will occur [6] Group 4: Investment Outlook - Eli Lilly is positioned to disrupt the healthcare space, particularly in weight loss and diabetes care, with a promising long-term growth outlook [7] - The entry into the Alzheimer's market further enhances the company's growth prospects across various medical areas [7] - Eli Lilly stock is viewed as a compelling opportunity for long-term investors at this time [7]

Eli Lilly logo is screened on a mobile phone for illustration photo. Krakow, Poland on April 9th, ... [+] 2024 (Photo by Beata Zawrzel/NurPhoto via Getty Images)NurPhoto via Getty ImagesEli Lilly stock (NYSE: LLY) has seen its stock rise by around 50% this year, outperforming the broader indices, with the S&P 500 up over 15%. The stock now trades at 63x projected 2024 earnings of $13.75 per share. Does this make the stock expensive? We don’t think so, considering that Eli Lilly’s revenues could grow over 75 ...

Companies like Novo Nordisk and Eli Lilly might soon have a determined competitor in their hottest product category.It wasn't so long ago when Novo Nordisk (NVO -2.84%) and Eli Lilly (LLY -4.50%) stocks were flying high thanks to their hotly popular weight loss drugs (Wegovy/Ozempic for Novo Nordisk and Zepbound/Mounjaro for Lilly).In the pharmaceutical industry, as in other sectors, a high-demand product encourages competitors to enter the same segment. News of a rapidly emerging rival put the hurt on both ...

Sometimes, the success of a company can take the stock so high that it pushes investors away. It is due to this reason that the management announces a stock split.While a stock split does not change anything in terms of the fundamentals of the company, it makes it easier for investors to own the stock. 2024 has been the year for stock splits and there are many stock split candidates that could make the big announcement.Right from the tech darling Nvidia (NASDAQ:NVDA) to the popular Chipotle Mexican Grill (N ...

INDIANAPOLIS, July 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2024 financial results on Aug. 8, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://invest ...

jetcityimage One of the most amazing growth stories, especially if you ignore the semiconductor space, over the past couple of years, has been pharmaceutical giant Eli Lilly and Company (NYSE:LLY). In just the past year, shares of the stock are up 88.5%. This comes on the back of tremendous growth driven by its weight loss drugs. As I detailed in a prior article, this has the potential to generate tremendous value for the company and its investors. But up until recently, the conversation has really only ...

Group 1: Industry Overview - Global obesity rates have nearly tripled since 1975 and are projected to affect over half the population by 2035, highlighting a significant public health challenge [1] - GLP-1 medications, initially developed for diabetes treatment, have shown effectiveness in appetite suppression and substantial weight loss, with additional benefits in slowing Parkinson's symptoms and reducing cardiovascular risks by approximately 20% [1] Group 2: Market Dynamics - Eli Lilly and Novo Nordisk dominate the weight-loss drug market, experiencing a surge in share prices due to high demand, although both companies saw declines of 6.3% and 4% respectively on July 18, 2024, amid rising competition [2] - Roche's new obesity drug candidate, CT-996, demonstrated a placebo-adjusted average weight loss of 6.1% in obese patients without Type 2 diabetes within four weeks, intensifying competition in the market [2][3] Group 3: Investment Opportunities - The Tema Obesity & Cardiometabolic ETF has about $83.2 million in assets, with top holdings including Vertex Pharma (6.17%), Amgen (5.47%), and Eli Lilly (5.29%), focusing on long-term growth in combating obesity [5] - The Amplify Weight Loss Drug & Treatment ETF, with a focus on Eli Lilly (15.71%) and Novo Nordisk (14.98%), aims to track the performance of the VettaFi Weight Loss Drug & Treatment Index [6] - The Roundhill GLP-1 & Weight Loss ETF includes significant holdings in Eli Lilly (20.93%) and Novo Nordisk (20.70%), targeting companies involved in weight loss pharmaceuticals and supplements [7][8]

Core Viewpoint - Eli Lilly has seen a significant increase of 47% in its stock price this year, prompting investors to seek alternative opportunities in the biotech sector, particularly companies developing weight loss drugs [1] Group 1: Viking Therapeutics - Viking Therapeutics has multiple upcoming data readouts that are expected to significantly impact its share price, particularly from its obesity-related clinical trials for VK2735 [2] - The phase 2 trial for the injectable version of VK2735 has been completed successfully, and the company is awaiting FDA assessment for a phase 3 trial [3] - VK2735 has shown promising results, with patients losing an average of approximately 13% of their body mass after 13 weeks of treatment, potentially outperforming existing market leaders like Eli Lilly's Mounjaro and Novo Nordisk's Wegovy [3][4] - The timeline for the phase 3 trial's conclusion remains unclear, but it is estimated to be within a couple of years [4] - The oral formulation of VK2735 has completed phase 1 trials, with phase 2 trials expected to start later this year, indicating potential for further stock movement [4] Group 2: Structure Therapeutics - Structure Therapeutics is also targeting the cardiometabolic therapy market with its candidate GSBR-1290, which is designed for weight loss and is formulated as a pill [6] - The phase 2a trials for GSBR-1290 have shown promising results, with patients experiencing a placebo-adjusted average weight loss of just over 6% over 12 weeks [6] - Phase 2b trials are anticipated to begin in the fourth quarter, with data expected to be released at various points in 2025, providing insights into the candidate's long-term efficacy and safety [7] - The phase 2b trial will last three times longer than the previous phase, increasing the stakes for Structure Therapeutics [7] - There is a risk that if the larger data set does not compare favorably to existing products, it could negatively impact the stock, despite the trials being deemed successful [8]

Group 1 - Eli Lilly has received approval from Chinese regulators to sell tirzepatide for weight loss, which is also the active ingredient in its diabetes treatment Mounjaro and weight-loss drug Zepbound [1][2] - The approval follows a similar approval for Novo Nordisk's weight-loss drug Wegovy in June [2] - A recent study indicated that tirzepatide resulted in greater weight loss compared to semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy [2] Group 2 - The competition between Eli Lilly and Novo Nordisk in the Chinese weight-loss market is expected to be significant, with the global weight-loss market projected to reach $77 billion annually by 2030 [3] - Eli Lilly has not disclosed when sales of tirzepatide will commence in China or the expected number of doses to be sold [3] - Following the announcement, Eli Lilly's shares increased by 1.4% to $860.50, marking a nearly 50% rise year-to-date, while Novo Nordisk's ADRs rose by 1.7% to $132.19, reflecting a 28% increase in 2024 [3]